How does checkpoint therapy work?

This complex has the dual function of binding pHLA, by the TCR, and triggering T-cell activation by CD3. Checkpoint therapy activates exhausted T cells to kill cancer cells and generally work best against tumors with high neoantigen burden and in patients with neoantigenic-reactive T cells.

Who is Checkpoint Therapeutics?

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.

Who owns Checkpoint Therapeutics stock?

Checkpoint Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.57%), Choreo LLC (0.16%), B. Riley Wealth Advisors Inc. (0.14%), Lindbrook Capital LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%).